Expression and clinical significance of ASB6 in colorectal cancer tissues
10.3760/cma.j.cn371439-20230523-00090
- VernacularTitle:ASB6在结直肠癌组织中的表达及临床意义
- Author:
Debao LIU
1
;
Ziwen SUN
;
Shoutang LU
;
Haidong XU
Author Information
1. 山东第一医科大学第一附属医院（山东省千佛山医院）肝病科，济南 250014
- Keywords:
Colorectal neoplasms;
ASB6;
Prognosis
- From:
Journal of International Oncology
2023;50(8):470-474
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the expression and clinical significance of ASB6 in colorectal cancer tissue.Methods:The cancer tissues and para-carcinoma tissues were selected from 106 patients with colorectal cancer admitted to the Department of Gastrointestinal Surgery, Third Affiliated Hospital of Shandong First Medical University from January 2015 to January 2018. Immunohistochemical method was used to detect the expression level of ASB6 protein in tissues, and the correlation between its expression and clinical pathological characteristics of patients was analyzed. At the same time, the expression of ASB6 mRNA in colorectal cancer tissues and para-carcinoma tissues was detected by quantitative real-time PCR (qRT-PCR). The Kaplan-Meier survival analysis method was used to explore the relationship between the expression of ASB6 and prognosis in colorectal cancer patients. The Cox regression model was used to analyze the independent prognostic factors of colorectal cancer patients.Results:The high expression rate of ASB6 in colorectal cancer tissues (67.9%, 72/106) was significantly higher than that in para-carcinoma tissues (10.4%, 11/106, χ2=73.67, P<0.001). Further analysis showed that the expression of ASB6 protein was significantly correlated with lymph node metastasis ( χ2=7.34, P=0.007) and TNM stage ( χ2=16.85, P<0.001). There was no significant correlation between the expression of ASB6 protein and age ( χ2=0.42, P=0.516), sex ( χ2=0.76, P=0.385), tumor size ( χ2=0.91, P=0.341), tumor location ( χ2=2.29, P=0.130), histological classification ( χ2<0.01, P>0.999), differentiation degree ( χ2=2.54, P=0.111) and distant metastasis ( χ2=3.38, P=0.066). qRT-PCR results showed that the expression level of ASB6 mRNA in colorectal cancer tissues was significantly higher than that in para-carcinoma tissues (5.37±0.13 vs. 3.39±0.09, t=-12.48, P<0.001). Kaplan-Meier survival analysis showed that the overall 5-year survival rates of patients in the ASB6 high expression group (72 cases) and the ASB6 low expression group (34 cases) were 45.8% and 73.5%, respectively ( χ2=6.82, P=0.009). Univariate survival analysis found that ASB6 protein expression ( HR=3.09, 95% CI: 1.25-7.65, P=0.015), lymph node metastasis ( HR=0.41, 95% CI: 0.21-0.82, P=0.011), distant metastasis ( HR=0.20, 95% CI: 0.10-0.42, P<0.001), and TNM stage ( HR=0.10, 95% CI: 0.03-0.32, P<0.001) were prognostic factors, while multivariate Cox survival analysis found that distant metastasis ( HR=0.22, 95% CI: 0.09-0.50, P<0.001) and TNM stage ( HR=0.25, 95% CI: 0.11-0.58, P<0.001) were independent prognostic factors. Conclusion:The expression of ASB6 in colorectal cancer tissues is significantly higher than that in para-carcinoma tissues, and the prognosis of patients with high expression of ASB6 is significantly worse than that of patients with low expression of ASB6. ASB6 can be used as an important indicator for early monitoring and postoperative survival assessment of colorectal cancer patients in the future.
